Mark Hatherill

17.1k total citations · 1 hit paper
194 papers, 6.7k citations indexed

About

Mark Hatherill is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Mark Hatherill has authored 194 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Infectious Diseases, 100 papers in Epidemiology and 61 papers in Surgery. Recurrent topics in Mark Hatherill's work include Tuberculosis Research and Epidemiology (129 papers), Mycobacterium research and diagnosis (49 papers) and Immunodeficiency and Autoimmune Disorders (40 papers). Mark Hatherill is often cited by papers focused on Tuberculosis Research and Epidemiology (129 papers), Mycobacterium research and diagnosis (49 papers) and Immunodeficiency and Autoimmune Disorders (40 papers). Mark Hatherill collaborates with scholars based in South Africa, United States and United Kingdom. Mark Hatherill's co-authors include Willem A. Hanekom, Thomas J. Scriba, Hassan Mahomed, Shane M. Tibby, Gregory Hussey, Michèle Tameris, IA Murdoch, Helen McShane, Charles Turner and J. Bruce McClain and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Mark Hatherill

183 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

2013 753 citations Michèle Tameris, Mark Hatherill et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Hatherill South Africa	45	4.1k	3.2k	2.3k	1.9k	815	194	6.7k
Deepali Kumar Canada	56	3.8k 0.9×	6.8k 2.1×	939 0.4×	1.6k 0.9×	300 0.4×	233	10.0k
Juan Gea‐Banacloche United States	30	1.0k 0.3×	4.0k 1.3×	1.3k 0.6×	1.1k 0.6×	316 0.4×	102	7.2k
Maurizio de Martino Italy	43	2.4k 0.6×	2.5k 0.8×	704 0.3×	778 0.4×	394 0.5×	244	6.2k
Michael G. Ison United States	51	2.9k 0.7×	5.7k 1.8×	599 0.3×	1.2k 0.6×	546 0.7×	234	8.5k
Court Pedersen Denmark	48	3.6k 0.9×	3.4k 1.1×	1.1k 0.5×	868 0.5×	418 0.5×	226	8.5k
Enrico Girardi Italy	50	6.1k 1.5×	5.2k 1.6×	736 0.3×	2.2k 1.2×	820 1.0×	333	8.5k
Asunción Moreno Spain	51	3.9k 0.9×	5.6k 1.8×	392 0.2×	1.3k 0.7×	338 0.4×	257	8.2k
Gitte Kronborg Denmark	42	2.6k 0.6×	2.2k 0.7×	1.1k 0.5×	410 0.2×	548 0.7×	168	6.5k
Andrew D. Badley United States	46	2.7k 0.6×	1.8k 0.6×	2.0k 0.9×	325 0.2×	1.4k 1.7×	195	6.6k
John W. Baddley United States	52	5.7k 1.4×	5.8k 1.8×	708 0.3×	539 0.3×	529 0.6×	183	9.0k

Countries citing papers authored by Mark Hatherill

Since Specialization

Citations

This map shows the geographic impact of Mark Hatherill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Hatherill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Hatherill more than expected).

Fields of papers citing papers by Mark Hatherill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Hatherill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Hatherill. The network helps show where Mark Hatherill may publish in the future.

Co-authorship network of co-authors of Mark Hatherill

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Hatherill. A scholar is included among the top collaborators of Mark Hatherill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Hatherill. Mark Hatherill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Cheng, C. Robert Horsburgh, Mark Hatherill, et al.. (2025). Trajectories of Interferon-Gamma Release Assay Results Over 2 Years in Independent Cohorts From China, South Africa, Tanzania, and the United States. CHEST Journal. 168(1). 33–42.

Churchyard, Gavin, Rein M G J Houben, Katherine Fielding, et al.. (2024). Implications of subclinical tuberculosis for vaccine trial design and global effect. The Lancet Microbe. 5(10). 100895–100895. 9 indexed citations

Sumner, Tom, Rebecca A. Clark, Allison Portnoy, et al.. (2024). Modelling the health and economic impacts of M72/AS01E vaccination and BCG-revaccination: Estimates for South Africa. Vaccine. 42(6). 1311–1318. 7 indexed citations

Murphy, Melissa, Sara Suliman, Hadn Africa, et al.. (2023). Newborn bacille Calmette-Guérin vaccination induces robust infant interferon-γ-expressing natural killer cell responses to mycobacteria. International Journal of Infectious Diseases. 130. S52–S62. 5 indexed citations

García‐Basteiro, Alberto L., Richard G. White, Dereck Tait, et al.. (2022). End-point definition and trial design to advance tuberculosis vaccine development. European Respiratory Review. 31(164). 220044–220044. 12 indexed citations

Mendelsohn, Simon C., Stanley Kimbung Mbandi, Andrew Fioré-Gartland, et al.. (2022). Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR. SHILAP Revista de lepidopterología. 2(1). 20 indexed citations

Coakley, Gillian, Tiffany Bouchery, Kathleen Shah, et al.. (2020). Immune serum–activated human macrophages coordinate with eosinophils to immobilize Ascaris suum larvae. Parasite Immunology. 42(7). e12728–e12728. 12 indexed citations

Zvada, Simbarashe, Paolo Denti, Mark Hatherill, et al.. (2019). A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. Antimicrobial Agents and Chemotherapy. 63(4). 20 indexed citations

Suliman, Sara, Melissa Murphy, Munyaradzi Musvosvi, et al.. (2019). MR1-Independent Activation of Human Mucosal-Associated Invariant T Cells by Mycobacteria. The Journal of Immunology. 203(11). 2917–2927. 47 indexed citations

10.

Mulenga, Humphrey, Stanley Kimbung Mbandi, Simon C. Mendelsohn, et al.. (2019). Performance of host blood transcriptomic signatures for diagnosing and predicting progression to tuberculosis disease in HIV-negative adults and adolescents: a systematic review protocol. BMJ Open. 9(5). e026612–e026612. 5 indexed citations

11.

Penn‐Nicholson, Adam, Thomas Hraha, Ethan Thompson, et al.. (2019). Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study. PLoS Medicine. 16(4). e1002781–e1002781. 68 indexed citations

12.

Suliman, Sara, Angelique Kany Kany Luabeya, Hennie Geldenhuys, et al.. (2018). Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial. American Journal of Respiratory and Critical Care Medicine. 199(2). 220–231. 76 indexed citations

13.

Fioré-Gartland, Andrew, Lindsay N. Carpp, Kogieleum Naidoo, et al.. (2017). Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. Tuberculosis. 109. 61–68. 19 indexed citations

14.

Nemes, Elisa, A C Hesseling, Michèle Tameris, et al.. (2017). Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin (BCG) for Infants of HIV Infected Mothers: A Phase 2 Randomized Controlled Trial.. Clinical Infectious Diseases. 1 indexed citations

15.

Schmidt, Bey‐Marrié, Leila Abdullahi, Humphrey Mulenga, et al.. (2017). Prevalence of latent TB infection and TB disease among adolescents in high TB burden countries in Africa: a systematic review protocol. BMJ Open. 7(3). e014609–e014609. 3 indexed citations

16.

Suliman, Sara, Hennie Geldenhuys, John L. Johnson, et al.. (2016). Bacillus Calmette–Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses. The Journal of Immunology. 197(4). 1100–1110. 106 indexed citations

17.

Ellis, Ruth D., Mark Hatherill, Dereck Tait, et al.. (2015). Innovative clinical trial designs to rationalize TB vaccine development. Tuberculosis. 95(3). 352–357. 23 indexed citations

18.

Hatherill, Mark, Tony Hawkridge, Francesca Little, et al.. (2010). Structured Approaches for the Screening and Diagnosis of Childhood Tuberculosis in a High Prevalence Region of South Africa/Approches Structurees Pour le Depistage et le Diagnostic De la Tuberculose Chez L'enfant Dans Une Region d'Afrique Du Sud Ou Cette Maladie Est Fortement prevalente/Sistemas Estructurados De Cribado Y Diagnostico De la Tuberculosis Infantil En Una Region De Alta Prevalencia De Sudafrica. Bulletin of the World Health Organization. 88(4). 312.

19.

Hatherill, Mark, Tony Hawkridge, Francesca Little, et al.. (2010). Sistemas estructurados de cribado y diagnóstico de la tuberculosis infantil en una región de alta prevalência de Sudáfrica. Bulletin of the World Health Organization. 88(4). 312–320. 1 indexed citations

20.

Hatherill, Mark, et al.. (2000). Exogenous Surfactant Supplementation in Infants with Respiratory Syncytial Virus Bronchiolitis. American Journal of Respiratory and Critical Care Medicine. 162(4). 1251–1256. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact